Burden of metastatic bone disease from genitourinary malignancies.
SourceExpert Review of Anticancer Therapy, 10, 11, (2010), pp. 1721-1733
1 november 2010
Article / Letter to editor
Display more detailsDisplay less details
Expert Review of Anticancer Therapy
SubjectONCOL 4: Quality of Care
Bone metastases are common among patients with stage IV genitourinary cancers. Most patients with bone metastases develop at least one debilitating and potentially life-limiting skeletal-related event. These events are associated with increased medical expenses and decreased quality of life. Current guidelines recommend screening for bone metastases in men with high-risk prostate cancer, but guidance for screening and treatment of bone metastases from genitourinary cancers varies by country and setting. Several bisphosphonates have been evaluated in the advanced genitourinary cancer setting. Zoledronic acid has demonstrated efficacy in significantly reducing the risk of skeletal-related events in patients with bone metastases from a broad range of solid tumors including prostate, renal and bladder cancers, and is recommended for preserving bone health.
Upload full text